Vincent Angotti is the CEO and a member of the board of directors at AcelRx Pharmaceuticals, Inc. Earlier, he was CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurological disorders.
Prior to that, Mr. Angotti was Senior Vice President of Sales and Marketing at Reliant Pharmaceuticals. He is a graduate of Cornell University and received an MBA, with honors, from Columbia University.
In this 3,776 word interview, exclusively in the Wall Street Transcript, Mr. Angotti delivers the upside rationale for his company to investors.
“The other side of the coin are drugs everyone’s heard of with not good praise: IV fentanyl and, to a lesser degree, IV sufentanil. The challenge with these drugs is that they come very fast in onset of action, in a matter of minutes. But as fast as they come on is as fast as they come off in their analgesic effects. The patient starts suffering from pain again. They have to continuously be re-dosed.”
AcelRx has developed an effective alternative:
“What Dr. Palmer did was she selected the molecule sufentanil for sublingual administration because of the reasons I mentioned before, from being highly lipophilic, non-ionized, allowing for transmucosal uptake, under the tongue, to a safety profile due to the very high therapeutic index. And number three, and most importantly, is this pharmacokinetic profile, what’s got a fast onset of analgesia under the tongue of about 15 minutes. It solves the morphine issue and has a nice duration of analgesic effect with just one dose over three to four hours, solving the issues with IV fentanyl and sufentanil, regarding the fast offset.
And finally, because it’s just one dose and because of the makeup of the drug and how it’s delivered under the tongue, it has a low level of medication in the blood, while it keeps you in the analgesic area, it typically doesn’t put you into the safety threshold of respiratory depression. It’s this beautiful triangle: There is fast onset, long duration, three to four hours, but safety, with a blunted blood concentration that doesn’t put patients typically into the respiratory depression zone.”
Get the complete investment thesis and all the details by reading the entire 3,776 word interview with Vincent Angotti, exclusively in the Wall Street Transcript.
AcelRx Pharmaceuticals Inc (ACRX) Prepares to Launch Lead Product Zalviso to Manage Postoperative Pain Nonintravenously
August 22, 2013
AcelRx Pharmaceuticals (ACRX) CEO Vincent Angotti Details Near Term Revenue Prospects
October 06, 2021
Glioblastoma Brain Cancer Therapy Now Being Tested in the U.S. by this Publicly Traded Company
October 05, 2020
Avenue Therapeutics (NASDAQ:ATXI) CEO and President Lucy Lu, M.D., has a Replacement for Medical Opiods
October 15, 2018
